C-Path Institute Exec Targets “Points Of Pain” In Device Development
This article was originally published in The Gray Sheet
Executive Summary
The Critical Path Institute's new Director of Medical Devices and Imaging, Ellen Feigal, MD, is working with device firms to identify key roadblocks to product development and clear the way to regulatory approval for those products
You may also be interested in...
CDRH Forecasts New Technological Trends, More Inter-Center Collaboration
FDA's Office of Science and Engineering Laboratories has revamped its research priorities and retrained staff to focus on improving both premarket and postmarket programs and regulatory science across CDRH
CDRH Forecasts New Technological Trends, More Inter-Center Collaboration
FDA's Office of Science and Engineering Laboratories has revamped its research priorities and retrained staff to focus on improving both premarket and postmarket programs and regulatory science across CDRH
Warfarin Labeling Change: Genetic Test Firms Anxiously Await FDA Action
Genetic test makers are lining up in anticipation of an FDA label change for the blood thinner warfarin that could significantly expand the market for companion diagnostics. They might still have a while to wait